Home > Boards > US OTC > Medical - Drugs > Roche Holding Ltd. (RHHBY)

The stock is up more than 37% over

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
investora2z Member Profile
 
Followed By 10
Posts 602
Boards Moderated 0
Alias Born 02/08/13
160x600 placeholder
New Hope in the Battle Against Ovarian Cancer NetworkNewsWire - 11/5/2019 8:45:00 AM
Delivering Precision Medicine’s True Potential: Big Data, Artificial Intelligence Identify New Cancer Therapeutics NetworkNewsWire - 10/29/2019 8:45:00 AM
U.K.'s Competition Watchdog Opens Probe into Roche Takeover of Spark Therapeutics Dow Jones News - 10/22/2019 2:46:00 AM
Roche: Phase 3 Study of Tecentriq, Avastin Combination a Success Dow Jones News - 10/21/2019 1:44:00 AM
Roche Says Outlook Is Improving as Revenue Grows Dow Jones News - 10/16/2019 1:48:00 AM
Roche Holding: Results From Tecentriq Study in Bladder Cancer Positive Dow Jones News - 9/30/2019 11:20:00 AM
Genentech Gets FDA Approval for Rituxan in Children With Two Rare Blood Vessel Disorders Dow Jones News - 9/27/2019 2:32:00 PM
Genentech Says Data Positive From Tecentriq Lung Cancer Study Dow Jones News - 9/27/2019 11:20:00 AM
U.K. Regulator to Probe Roche's Acquisition of Spark Therapeutics Dow Jones News - 9/25/2019 2:54:00 AM
Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers NetworkNewsWire - 9/24/2019 8:45:00 AM
Genentech Gets FDA Breakthrough Designation for Gazyva in Lupus Nephritis Dow Jones News - 9/18/2019 6:40:00 AM
Genentech Receives FDA Accelerated Approval for Cancer Treatment Dow Jones News - 8/15/2019 4:36:00 PM
Roche Extends Offer Period for Spark Therapeutics Dow Jones News - 7/31/2019 1:48:00 AM
Roche: CHMP Backs Tecentriq in Extensive-Stage Small-Cell Lung Cancer Dow Jones News - 7/26/2019 10:46:00 AM
Roche Sales Boosted by New Drug Pipeline -- Update Dow Jones News - 7/25/2019 4:14:00 AM
Roche 1st Half Profit, Sales Grew; Raises Full-Year Sales Guidance Dow Jones News - 7/25/2019 1:46:00 AM
Sanofi Gets Exclusive Over-The-Counter Rights to Tamiflu in the US From Roche Dow Jones News - 7/23/2019 1:47:00 AM
AbbVie Says FDA Lifts Partial Hold on Phase 3 Trial Dow Jones News - 6/24/2019 9:38:00 AM
Exelixis: Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint Dow Jones News - 6/20/2019 7:37:00 PM
Genentech Gets FDA Priority Review For Rituxan in Children With Rare Blood Vessel Disorders Dow Jones News - 6/12/2019 6:48:00 AM
Genentech's Gazyva Meets Main Endpoints in Lupus Nephritis Study Dow Jones News - 6/11/2019 7:25:00 AM
Roche Says Peter Voser to Step Down as Director; Makes Changes to Executive Committee Dow Jones News - 6/11/2019 1:51:00 AM
Roche's Genentech Gets FDA Priority Approval For Polivy Regimen Dow Jones News - 6/10/2019 12:58:00 PM
Correction to Roche, Spark Therapeutics Article Dow Jones News - 6/10/2019 2:12:00 AM
Roche, Spark Therapeutics Extend Tender Offer Period After FCA Requests More Information Dow Jones News - 6/10/2019 1:52:00 AM
investora2z   Sunday, 04/07/13 02:19:38 AM
Re: None
Post # of 138 
The stock is up more than 37% over the past 52 weeks and hence beats the S&P which has grown by 12%. It is making new highs every day and has been on a steady uptrend since February 2009 when it was around $28. The uptrend has accelerated since May 2012 when it was around $39. It is trading well above its 200 DMA of $52.20 and the 50 DMA of $57.51. The recent volumes have been tremendous as the 10 day average is significantly higher (635K) compared with the 3 month average of 493K. In addition to the capital appreciation, the company has been paying increasing dividends over several years. The current payout is around 66% and the company has been growing well. Recently, it was reported that Roche Holding AG had obtained the European approval for its breast cancer drug Perjeta. Roche is heavily committed to research on cancer drugs. The company has numerous drugs in the pipeline which are at various stages of trials / filing. Cancer research is a very competitive field with several big and small companies competing for launching drugs for various types. There are smaller companies like Senesco Technologies (SNTI) which are researching on cancer drugs which have extremely interesting mechanisms of action. Even those trials are progressing extremely well. For Roche, it is imperative for the company to come out with new drugs. In fact, this is the story of all pharma companies. Patent expirations need to be filled up with new drugs to fill the void created by declining sales. The declines are sudden because the generic drug manufacturers are always waiting to launch cheaper versions of successful drugs. The other areas of pharma research by Roche include Immunology, Ophthalmology, Virology, CardioMetabolism, Neuroscience etc. Long term success is directly dependent on the new product launches.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist